Sanofi 6-K: Frexalimab MS Data & More
Ticker: SNYNF · Form: 6-K · Filed: May 2, 2024 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | May 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-data, pharmaceuticals, multiple-sclerosis
TL;DR
Sanofi 6-K drops: Frexalimab MS Phase 2 data looks good, more updates coming.
AI Summary
Sanofi filed a Form 6-K on May 2, 2024, incorporating four press releases published in April and May 2024. Notably, Exhibit 99.1, dated April 17, 2024, presented new 48-week Phase 2 data for frexalimab, a treatment for multiple sclerosis, suggesting potential for high and sustained efficacy.
Why It Matters
This filing provides updates on Sanofi's clinical trial progress, specifically highlighting promising data for a new multiple sclerosis treatment, which could impact future revenue streams and patient care.
Risk Assessment
Risk Level: low — The filing is a routine report of foreign private issuers and primarily contains press releases, not significant new financial events or strategic shifts.
Key Players & Entities
- Sanofi (company) — Registrant
- frexalimab (drug) — Treatment for multiple sclerosis
- April 17, 2024 (date) — Date of press release
- May 2, 2024 (date) — Filing date
FAQ
What is the significance of the frexalimab Phase 2 data mentioned in Exhibit 99.1?
The data, collected over 48 weeks, supports the potential for high and sustained efficacy of frexalimab in treating multiple sclerosis.
What form is Sanofi filing with the SEC?
Sanofi is filing a Form 6-K, which is a Report of Foreign Private Issuer.
When were the press releases incorporated into this filing published?
The press releases were published in April and May 2024.
What is Sanofi's primary business classification according to the filing?
Sanofi is classified under Standard Industrial Classification code 2834, which is Pharmaceutical Preparations.
What is the principal executive office address for Sanofi?
Sanofi's principal executive offices are located at 46, avenue de la Grande Armée, 75017 Paris, France.
Filing Stats: 247 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-05-02 15:52:58
Filing Documents
- d793882d6k.htm (6-K) — 10KB
- d793882dex991.htm (EX-99.1) — 23KB
- d793882dex992.htm (EX-99.2) — 21KB
- d793882dex993.htm (EX-99.3) — 11KB
- d793882dex994.htm (EX-99.4) — 42KB
- g793882g0502053257638.jpg (GRAPHIC) — 3KB
- g793882g0502053401168.jpg (GRAPHIC) — 3KB
- g793882g86v74.jpg (GRAPHIC) — 2KB
- 0001193125-24-129331.txt ( ) — 118KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: May 2, 2024 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3